In the wake of the patent rejection, companies such as Natco Pharma may begin work on their own, less expensive versions of the HCV drug. Larger pharmaceutical companies, such as Pfizer and Novartis AG, have had patents rejected in India as well, due to stricter standards, according to the report.
Gilead Sciences has the option to appeal the patent rejection.
More articles on gastroenterology:
Are gastroenterologists looking for new avenues to increase practice revenue? 10 statistics
5 gastroenterologists leading GI mega-practices
7 New Year’s Resolutions from the AGA
